Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer.

These findings suggest that peri-menopause/menopause represents a unique window of time during which metformin may be highly effective in women with established, or at high risk for developing, breast cancer.